Members of the family Filoviridae cause severe, often fatal disease in humans, for which there are no approved vaccines and only a few experimental drugs tested in animal models. Retro-2, a small molecule that inhibits retrograde trafficking of bacterial and plant toxins inside host cells, has been demonstrated to be effective against a range of bacterial and virus pathogens, both in vitro and in animal models. Here, we demonstrated that Retro-2 and its derivatives, Retro-2.1 and compound 25, blocked infection by Ebola virus and Marburg virus in vitro. We show that the derivatives were more potent inhibitors of infection as compared to the parent compound. Pseudotyped virus assays indicated that the compounds affected virus entry into cells while virus particle localization to Niemann-Pick C1-positive compartments showed that they acted at a late step in virus entry. Our work demonstrates a potential for Retro-type drugs to be developed into anti-filoviral therapeutics.
Introduction
Filoviruses are a diverse group of viruses that share a common filamentous morphology and genome structure. The filovirus genome is approximately 20 kb long and is a single-stranded RNA molecule in a negative orientation encoding seven structural proteins (Sanchez et al., 2007) . Nucleoprotein NP encapsidates the genome and replication intermediates and, together with RNA-dependent polymerase L, phosphoprotein VP30, and polymerase cofactor VP35, forms the viral ribonucleoprotein (RNP) complex. NP, L, and VP35 facilitate genome transcription and replication for both Ebolavirus and Marburgvirus genera (Muhlberger et al., 1998 (Muhlberger et al., , 1999 . The virion surface is studded with glycoprotein complexes (GP), which bind to host cell receptor(s) (Moller-Tank et al., 2013; Shimojima et al., 2006; Simmons et al., 2003; Takada et al., 2004) and mediate uptake into the cell and trafficking through early and late endosomes (Nanbo et al., 2010; Saeed et al., 2010) . Once in endosomes, GP undergoes proteolysis which is essential for interaction with Niemann-Pick type C1 (NPC1) protein (Chandran et al., 2005; Miller et al., 2012; Schornberg et al., 2006) . The binding of GP to NPC1 precedes virus fusion with endosomal membranes to release the genome into the cytoplasm (Carette et al., 2011; Cote et al., 2011) .
The majority of filoviruses cause severe hemorrhagic fever disease in humans with a mean fatality rate being approximately 55% (Bausch et al., 2006; Feldmann and Geisbert, 2011; Roddy, 2014) . Since the first filovirus discovery in 1967 (Siegert et al., 1968) , annual outbreaks of human filovirus disease have been reported involving viruses across each genera, making it virtually impossible to predict the identity of the virus for the next outbreak (Roddy, 2014) . There have also been reports of import and spread of the disease into areas outside endemic regions (Kmietowicz, 2014; Lyon et al., 2014; Rubin and Baden, 2014) . Progress toward a broad-spectrum anti-filovirus disease therapy, acting against multiple members of the family, has been slow, with most attention being directed toward variants of one virus, Ebola virus (EBOV), of the Ebolavirus genus. Antibody cocktails targeting the GP show high efficacy in non-human primate models and tend to be EBOVspecific (Davey et al., 2016) , although neutralizing cross-species antibodies have been recently identified (Holtsberg et al., 2015) . Few other drug candidates show efficacy in animal models (Gehring et al., 2014; Johansen et al., 2013; Madrid et al., 2013; Oestereich et al., 2014; Warren et al., 2014) . Ribavirin, a nucleoside analog with broad-spectrum antivirus activity against several RNA and DNA viruses, including Lassa fever virus and hantavirus, showed limited efficacy against EBOV and Marburg virus (MARV) in animal models of the disease (Huggins, 1989) . To date, the most promising drug candidates acting against many members of the filovirus family are GS-5734 and BCX4430, which https://doi.org/10.1016/j.antiviral.2017.11.016 Received 27 July 2017; Received in revised form 17 November 2017; Accepted 18 November 2017 similarly to ribavirin, are nucleoside analogs interfering with virus replication (Warren et al., 2014 (Warren et al., , 2016 . Despite good efficacy, these drugs use the same mechanism to inhibit infection.
Viruses critically depend on host cellular factors to establish productive infection. These cellular factors are large in number, of wide variety, and are therefore attractive targets of antiviral drugs that may offer reduced chances of emergence of drug resistance in viruses (Bekerman and Einav, 2015) . Targeting host factors and pathways critical for infection across filovirus genera also provides a way to develop broad-spectrum therapies. Previously, Retro-2 was identified as an inhibitor of endosome-to-Golgi retrograde transport of the plant toxin ricin and bacterial Shiga toxin in cell culture and for treatment of intoxication in the animal model (Stechmann et al., 2010) . Moreover, Retro-2 exhibited broad-spectrum activity providing protection against other pathogens by inhibiting vesicular trafficking. Retro-2 blocked invasion of cells by the intracellular parasite Leishmania (Canton and Kima, 2012; Wanderley et al., 2006) , as well as replication of non-enveloped viruses, including polyoma-, papilloma-, and adeno-associated viruses (Carney et al., 2014; Nelson et al., 2013; Nonnenmacher et al., 2014) . However, the efficacy of this class of compounds has not been examined against enveloped viruses, such as filoviruses. In this study, we investigated the efficacy and mechanism of Retro-2 and its dihydroquinazolinone derivatives, Retro-2.1 and compound 25, of inhibition of EBOV and MARV infection. (A) HeLa cells were preincubated with Retro-2 at indicated concentrations for 1 h or equivalent concentration of vehicle (DMSO), or left untreated and then challenged with EBOV-eGFP in the presence of the compound. Twenty-four hours later, cells were fixed, stained with Hoechst 33342 dye, and imaged (top and middle panels). Numbers of nuclei and eGFP-positive (infected) cells were counted using CellProfiler software. The relative infection efficiencies were calculated by dividing the number of infected cells by the number of nuclei. The percentages of infected cells in DMSO-and Retro-2-treated samples are reported relative to the infection efficiency in untreated cells and are averages ± standard deviations (SDs) of 3 replicates (right panel). Each data set is representative of three independent experiments. (B) HeLa cells were treated with Retro-2 (50 μM) or equivalent concentration of DMSO, Triton X-100 (0.01%, v/v), or left untreated. After 24 h, cell viability was assessed by using CellTiter-Glo luminescent reagent. (C) Equal amounts of EBOV-eGFP were incubated with Retro-2 (50 μM) or equivalent concentration of DMSO, or left untreated. After 30 min, samples were diluted 100-fold and overlaid onto HeLa cells. Infection efficiencies were determined as in (A). (D) Huh-7 cells were treated with Retro-2 or DMSO, challenged with EBOV-eGFP, imaged, and analyzed as described in (A). (E) Huh-7 cells were treated with Retro-2 (50 μM) or equivalent concentration of DMSO, Triton X-100 (0.01%, v/v), or left untreated for 24 h. Cell viability was assessed as in (B).
Materials and methods

Cells
Human cervical carcinoma (HeLa), human embryonic kidney (HEK) 293T, and African green monkey (Vero) cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Thermo Fisher Scientific, Waltham, MA). 293FT (Thermo Fisher Scientific, Waltham, MA) cells were cultivated in DMEM supplemented with 10% FBS and 0.5 mg/mL G418 (Thermo Fisher Scientific, Waltham, MA). All cells were maintained at 37°C with 5% CO 2 .
Viruses
All experiments with replication competent EBOV and MARV were performed in the biosafety level 4 (BSL-4) laboratory at the Texas Biomedical Research Institute (San Antonio, TX). The wild-type EBOV variant Mayinga (NCBI accession number NC_002549) and MARV strain Musoke (NCBI accession number NC_001608) were obtained from the virus repository at the Texas Biomedical Research Institute, San Antonio, TX. The recombinant EBOV variant Mayinga expressing enhanced GFP (EBOV-eGFP) was kindly provided by Heinz Feldmann (NIH, Hamilton, MT). The viruses were amplified in Vero cells in DMEM containing 2% FBS for 7 days. The culture supernatants containing the viruses were clarified of cell debris, overlaid over a 20% sucrose cushion in PBS, and centrifuged at 4°C at 28,000 rpms for 2 h. The pellets were resuspended in PBS. The titer of EBOV-eGFP stock was determined by incubating serial dilutions of the stock on Vero cells for 24 h. Infected cells were fixed with 10% buffered formalin (Sigma, St. Louis, MO) for 24 h, and then stained with Hoechst 33342 dye (Thermo Fisher Scientific, Waltham, MA) to identify cell nuclei. Cells were photographed using a Nikon Ti-Eclipse microscope running high content analysis software (Nikon, Tokyo, Japan). The numbers of cell nuclei and infected cells were counted using Cell Profiler software (Broad Institute, Boston, MA) with pipelines developed by the authors (available upon request). To determine titers of the wild-type EBOV and MARV, Vero cells were incubated with 10-fold serial dilutions of the viruses at 37°C for 1 h. After the virus was removed, the cells were overlaid with DMEM containing 2% FBS and 1.5% methyl cellulose (Sigma, St. Louis, MO). Ten days after infection, cells were fixed and stained with gentian violet dye (Ricca Chemical Company, Arlington, TX) to identify virus foci.
Antibodies and inhibitors
Antibodies used in this study were rabbit polyclonal antibody to myc tag (Cell Signaling Technology, Danvers, MA), mouse monoclonal antibody, clone 4F3, to EBOV GP and rabbit polyclonal antibody to MARV VLPs (IBT Bioservices, Gaithersburg, MD).
Dimethylsufoxide (DMSO) was purchased from ATCC (Manassas, VA). Cycloheximide was from EMD Millipore (Billerica, MA). Triton X-100 was from Sigma (St. Louis, MO). CA074 and tetrandrine were from Enzo Life Sciences (Farmingdale, NY).
Retro-2, Retro-2.1, and compound 25 were synthesized by JeanChristophe Cintrat and Romain Noël as previously described (Gupta et al., 2014; Noel et al., 2013) . Retro-2 spontaneously cyclizes to Retro-2 cycl (Fig. 3A ) in aqueous solutions (Yu et al., 2013) ; the mixture is referred to as Retro-2 herein. The racemic mix of Retro-2.1 was used in this study.
Plasmids
The plasmids for the expression of EBOV proteins contained portions of the EBOV variant Mayinga genome. pcDNA3-VP40, pcDNA3-GP, and p3E5E-Luc constructs were described previously (Muhlberger et al., 1999; Saeed et al., 2008 Saeed et al., , 2010 . The EBOV NP cDNA was amplified by reverse transcription (RT)-PCR using total RNA extract of EBOV-infected Vero cells and a forward primer (5′-GCGC GAATTC ATG GAT TCT CGT CCT CAG AAA ATC TGG ATG-3′) and a reverse primer (5′-GCGC CTCGAG TCA CTG ATG ATG TTG CAG GAT TGC CAT GAA TTT ATT C-3′), EBOV VP30 gene was amplified by using a forward primer (5′-GCGC GAATTC ATG GAA GCT TCA TAT GAG AGA GGA CGC-3′) and a reverse primer (5′-GCGC CTCGAG TTA AGG GGT ACC CTC ATC AGA CCA TGA G-3′), EBOV VP35 was amplified by using a forward primer (5′-GCGC CCCGGG ATG ACA ACT AGA ACA AAG GGC AGG GG-3′) and a reverse primer (5′-GCGC GAGCTC TCA AAT TTT GAG TCC AAG TGT TTT ACC ATC TTG AAG-3′), and EBOV L was amplified by using a forward primer (5′-ATAT GCGGCCGC ATG GCT ACA CAA CAT ACC CAA TAC CCA G-3′) and a reverse primer (5′-GCGC GAGCTC TCA ATC AAA CCT GTA GAG ACC ATC CGG AAA TAA AC -3′). The PCR products were cloned into the protein expression vector pCAGGS/MCS (Kobasa et al., 1997; Niwa et al., 1991) , kindly provided by Dr. Yoshihiro Kawaoka (University of Wisconsin, Madison, WI), using standard cloning techniques to generate pC-NP, pC-VP30, pC-VP35, and pC-L, and the sequences were confirmed.
Plasmid encoding the vesicular stomatitis virus G, pLP/VSVG, was purchased from Thermo Fisher Scientific (Waltham, MA). Plasmid encoding the 10A1 murine leukemia virus GP, pMLV10A1, retrovirus recombinant genome CSII-CMV-Luc, pBabe-βGal, and pCMV-Δ8/9 plasmids were described previously (Davey et al., 1999; Miller and Chen, 1996; Sakurai et al., 2009 ). CSII-CMV-Luc plasmid was generously provided by Dr. Masao Matsuoka (Kyoto University, Kyoto, Japan), and a plasmid encoding myc-tagged NPC1 was a gift from Dr. Kartik Chandran (Albert Einstein College of Medicine, Bronx, NY).
Virus infection assay
To test impact of Retro-2, Retro-2.1, and compound 25 on virus infection in HeLa cells or Retro-2 in Huh-7 cells, cells grown in 96-well plates were either left untreated or pretreated with the compounds or DMSO (≤0.5%) in 2-fold serial dilutions for 1 h and then challenged with EBOV-eGFP, wild-type EBOV, or MARV at an MOI of 0.01 for 24 h. Subsequently, infected cells were fixed and stained with Hoechst 33342 dye. The wild-type EBOV-infected cells were also stained with anti-GP antibody, and the MARV-infected cells were stained with anti-VLP antibody. Cells were photographed and analyzed as described above for EBOV-eGFP. The infection rate was calculated as the ratio of infected cells to cell nuclei. Dose-response curves were fitted using Graphpad Prism 7.02 (www.graphpad.com) by non-linear regression and using the "[Inhibitor] vs response (three parameters)" equation.
To test whether Retro-2 affected viability of EBOV, 10 5 FFUs of EBOV-eGFP were incubated with Retro-2 to a final concentration of 50 μM or equal amount of DMSO as a control, or left untreated at 37°C for 30 min. All treatments were performed in triplicate. Then, samples were diluted 100-fold and overlaid onto HeLa cells grown in 96-well plates at an MOI of 0.01. After 24 h, cells were fixed, stained, imaged, and analyzed as described above.
Cell viability assay
To test if Retro compounds affected health of HeLa or Huh-7 cells during infection, CellTiter-Glo luminescent kit (Promega, Madison, WI) was used to determine the number of metabolically active cells. HeLa cells grown in a 96-well plate were left untreated or incubated with DMSO, Retro-2, Retro-2.1, or compound 25 to the final concentration of 50 μM. Detergent Triton X-100 at 0.01% compromises cell viability and was therefore used as a control for cytotoxicity. All treatments were performed in triplicate. After 24 h, luciferase activity was measured according to the manufacturer's protocol. The luminescence was measured using a GloMax-20/20 luminometer (Promega, Madison, WI).
Pseudotyped HIV-1
To generate EBOV GP, MLV GP, or VSV G pseudotyped HIV-1 particles encoding the firefly luciferase gene (HIV-1-EBOV-GP, HIV-1-MLV10A1-GP, or HIV-1-VSV-G), 293FT cells grown in 100-mm dishes were cotransfected with 5 μg of CSII-CMV-Luc, 5 μg of the pCMV-Δ8/9 (gifted by Dr. Hiroyuki Miyoshi, RIKEN, Tsukuba, Japan), and either 1 μg of pcDNA3-GP, 5 μg of pMLV10A1, or 1 μg of pLP/VSVG using CaCl 2 method. The supernatants were collected 48 h after transfection, passed through a 0.4-μm-size-pore filter, laid over a 20% sucrose-PBS cushion, and subjected to ultracentrifugation at 28,000 rpm for 2 h at 4°C. Pellets were resuspended in PBS at 4°C for 18 h. Virus titers were determined in HeLa cells grown in 96-well plates using serial 2-time dilutions. After 48 h, luciferase activity was measured using Steady-Glo luciferase assay buffer (Promega, Madison, WI) according to the supplier's recommendations. The luminescence was measured using a GloMax-20/20 luminometer. Either an unpaired two-tailed t-test or a one-way ANOVA followed by Dunnett's multiple comparison test for one variable was used to assess statistical differences in infection efficiencies of cells treated with DMSO and each of the Retro compounds. P values were considered statistically significant if less than 0.05.
Minigenome assay
p3E5E-Luc plasmid, encoding the firefly luciferase reporter gene, was provided by Elke Muhlberger (Boston University, MA). To generate synthetic EBOV minigenome encoding the firefly luciferase gene, p3E5E-Luc was linearized with SalI (New England Biolabs, Ipswich, MA) and used as a template to synthesize RNA using MEGAscript T7 kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol. The RNA was purified using RNA-Bee reagent (AMS Biotechnology, United Kingdom) and resuspended in diethyl pyrocarbonate-treated water (Thermo Fisher Scientific, Waltham, MA).
To test whether Retro-2, Retro-2.1, or compound 25 affected EBOV minigenome activity, 10 5 HEK 293T cells were electroporated with 1 μg minigenome RNA, 0.065 μg pC-NP, 0.065 μg pC-VP35, 0.25 μg pC-VP30, and 0.5 μg pC-L using the Neon transfection system (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol. The electroporated cells were plated into wells of 24-well dishes. Sixteen hours later, cells were incubated with each compound to a final concentration of 20 μM or DMSO as a control. All treatments were performed in triplicate. After 24 h, the culture media were removed, and cells were assessed for firefly luciferase activity as described above.
EBOV GP cleavage assay
To test if Retro compounds affected EBOV infection prior or after GP proteolysis, 10 4 of EBOV-eGFP particles were incubated with 0.5 mg/ 
VLP preparation
293FT cells grown in 100-mm dishes were transfected with 5 μg of plasmids encoding EBOV structural proteins, pcDNA3-VP40 and pC-NP, and 1 μg of pcDNA3-GP using CaCl 2 method. After 18 h, media was replaced. Forty-eight hours after transfection, the growth media was collected and cell debris pelleted. The supernatants were laid over 20% sucrose cushion in PBS and spun at 4°C at 28,000 rpm for 2 h. The pellets were resuspended in PBS at 4°C for 18 h and stored at −80°C until needed.
VLP-NPC1 colocalization
HeLa cells grown in 12-well dishes were transfected with 1 μg of a plasmid encoding myc-tagged NPC1 using TransIT LT1 (Mirus Bio LLC, Madison, WI) according to the manufacturer's protocol. Forty-eight hours later, cells were pretreated with Retro-2, Retro-2.1, or compound 25 to a final concentration of 20 μM or DMSO as a control for 1 h and then incubated with VLPs in the presence of each compound for 4 h. Subsequently, samples were washed with PBS, fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 20 min, permeabilized with 0.1% Triton X-100 in PBS for 10 min, and blocked with 5% goat serum (Thermo Fisher Scientific, Waltham, MA) in PBS for 1 h at room temperature. VLPs and NPC1 were identified by staining samples with an anti-GP and an anti-myc antibodies, respectively, at 4°C overnight, followed by Alexa Fluor-conjugated anti-mouse and anti-rabbit antibodies (Thermo Fisher Scientific, Waltham, MA). To define cell cytoplasm and nuclei, samples were stained with HCS CellMask Blue Stain (Thermo Fisher Scientific, Waltham, MA). Z-stack immunofluorescence imaging was done using 100x lens on 20 cells in each sample. The images were subjected to deconvolution by AutoQuant X3 software (MediaCybernetics, Rockville, MD) and then 3D Fig. 2 . Retro-2 inhibits EBOV entry. (A) To assess the effect of Retro-2 on EBOV transcription and/or replication, 293T cells were transfected with EBOV minigenome RNA encoding firefly luciferase gene and plasmids pC-NP, pC-VP30, pC-VP35, and pC-L encoding the EBOV polymerase complex. Twenty-four hours later, cells were treated with DMSO, Retro-2 (20 μM), or cycloheximide (1 μg/mL). Luciferase activity was determined after another 24 h. Three independent experiments were performed, and the averages ± SDs are reported. (B) HeLa cells were preincubated with DMSO or Retro-2 (20 μM) for 1 h and then transduced with HIV-1 particles pseudotyped with EBOV-GP, MLV10A1-GP, or VSV-G, in the presence of the compound. Luciferase activity was measured after 48 h (RLUs). An unpaired two-tailed t-test was used to assess a statistical difference between infection efficiencies of EBOV-GP-pseudotyped virus in DMSO and Retro-2-treated cells. A P value < 0.05 was considered statistically significant and was determined to be < 0.01.
(caption on next page) O. Shtanko et al. Antiviral Research 149 (2018) 154-163 reconstruction using Imaris software (Bitplane, Zurich, Switzerland). The experiment was repeated 3 times. The number of VLPs localizing to NPC1-positive compartments was determined by manual counting. The percentage of virions colocalizing with NPC1 was calculated as a ratio of VLPs found in NPC1-positive compartments to total number of VLPs using Excel software (Microsoft). A one-way ANOVA test was used to assess statistical differences between DMSO and Retro compound treated samples.
Results
Retro-2 inhibits EBOV infection
Retro-2 was shown to block infection by various pathogens and parasites and intoxication by biological toxins, both in cell culture and in mice (Canton and Kima, 2012; Stechmann et al., 2010) , and viruses in cell culture (Carney et al., 2014; Nelson et al., 2013; Nonnenmacher et al., 2014) . Several of these pathogens depend on either macropinocytosis or phagocytosis to invade cells (Day and Schelhaas, 2014; Iversen et al., 2012; Kuwae et al., 2001; Wanderley et al., 2006) . Because filovirus uptake into cells is also known to require macropinocytosis, we tested if Retro-2 affected EBOV infection. HeLa cells pretreated with up to 50 μM of Retro-2 or DMSO as a control were challenged with a recombinant replication-competent EBOV encoding green fluorescent protein as a marker of infection (EBOV-eGFP). Similarly to that seen with the other pathogens, EBOV infection was inhibited in a dose-dependent manner, yielding an EC 50 of 10.2 ± 3.0 μM (Fig. 1A) . No cytotoxicity was observed at the maximum tested concentration of 50 μM (Fig. 1B) . To eliminate the possibility that Retro-2 affected viability of EBOV, virus was incubated with the compound at the highest concentration tested in the infection assay, 50 μM, or DMSO as a control, then added onto HeLa cells after a 100-fold dilution to assure a non-inhibitory concentration of Retro-2 (Fig. 1A) . The treatment had no effect on EBOV infection efficiency (Fig. 1C) , indicating that Retro-2 blocks a cellular factor(s) necessary for virus replication cycle.
We next tested if the anti-filoviral activity of Retro-2 would extend to other cell types. Since human liver is an important site of virus infection and replication during the course of the disease (Rasmussen, 2017) , Huh-7 cells, a human hepatoma cell line, was used. Similarly to what was observed in HeLa cells, Retro-2 was able to inhibit EBOV infection in a dose-dependent manner, with an EC 50 determined to be 23.3 ± 10.0 μM (Fig. 1D) , while being non-toxic at the maximum tested concentration of 50 μM (Fig. 1E) .
Since we measured infection at 24 h, corresponding to one round of virus replication, Retro-2 was likely impacting virus infection by blocking either cell entry or virus genome replication.
Retro-2 inhibits EBOV cell entry
We examined the mechanism of action of Retro-2 by identifying the step of virus infection that was inhibited. A minigenome system for EBOV has been established and allows quantification of genome transcription/replication efficiency without the need for virus cell entry (Muhlberger et al., 1999) . Cells were transfected with plasmids encoding the viral polymerase complex and a minigenome encoding the firefly luciferase gene. Treatment with Retro-2 resulted in a 3-fold increase in minigenome activity ( Fig. 2A) compared to cells treated with DMSO, whereas treatment with cycloheximide, an inhibitor of protein synthesis in eukaryotic cells (Obrig et al., 1971) , resulted in a 99% reduction in luciferase activity. The concentration of Retro-2 of 20 μM was selected giving 80% inhibition of virus infection (Fig. 1A) . Also, a previous report studying the effect of Retro-2 on the retrograde transport of Shiga toxin demonstrated compound efficacy in HeLa cells at this concentration (Stechmann et al., 2010) . These results show that Retro-2 does not inhibit virus transcription/replication, instead enhancing it, suggesting that the loss of infection seen with wild-type virus is due to a step other than transcription or replication.
To test whether virus entry was affected, pseudotyped lentiviruses bearing the EBOV GP (HIV-1-EBOV-GP), murine leukemia virus 10A1 GP (HIV-1-MLV-10A1-GP), or vesicular stomatitis virus G (HIV-1-VSV-G) and encoding a firefly luciferase reporter gene were used. EBOV entry into cells requires trafficking to late endosome acidified compartments where its GP mediates fusion of viral and host membranes to release its genome into the cytoplasm for replication (Chandran et al., 2005; Dolnik et al., 2008) . In contrast, MLV strain 10A1 enters cells at the plasma membrane through a pH-independent mechanism (Blanchard et al., 2006) and therefore served as a control for non-specific disruption of reporter expression or cell viability. VSV undergoes endocytosis to traffic to early endosomes where the viral glycoprotein triggers fusion with the cell membrane (Simmons et al., 2015) . HeLa cells pretreated with 20 μM Retro-2 or DMSO were incubated with either pseudotyped virus for 48 h in the presence of the compound. Retro-2 treatment inhibited HIV-1-EBOV-GP infection by > 50% (P < 0.01), while it enhanced infection of HIV-1-MLV-10A1-GP by > 2-fold and HIV-1-VSV-G by > 3-fold (Fig. 2B) . The increase in HIV-1-MLV-10A1-GP infection suggests that Retro-2 either blocks a degradation pathway, which is unproductive for this virus type, or enhances HIV-1 core integration and/or reporter expression. The even larger increase in HIV-1-VSV-G infection indicates that the compound affects EBOV entry into cells at a step downstream of early endosomes. In either case, the 50% drop in EBOV pseudotype infection is consistent with Retro-2 inhibition of virus entry.
3.3. Retro-2 derivatives, Retro-2.1 and compound 25, are more potent inhibitors of EBOV infection and entry While Retro-2 appears to inhibit entry into cells, it also significantly enhanced EBOV transcription and/or replication ( Fig. 2A) . Since this was an undesirable property for a potential therapeutic, we sought derivatives that blocked virus infection, but did not elevate genome transcription/replication. Two derivatives of Retro-2 (Noel et al., 2013; Park et al., 2012) , Retro-2.1 and compound 25 (Gupta et al., 2014; Noel et al., 2013) , had been obtained after structure-activity studies for increased activity against ricin and Shiga toxins. Each share a 2-(1,3-thiophene) dihydroquinazolinone scaffold with a pendant 2-methyl 1,3- Fig. 3 . Retro-2 derivatives, Retro-2.1 and compound 25, are more potent inhibitors of EBOV infection and entry. (A) Chemical structure of the cyclized form of Retro-2, Retro-2 cycl , and its derivatives, Retro-2.1 and compound 25. Modified side groups are shown in red. (B) HeLa cells were preincubated with Retro-2, Retro-2.1, or compound 25 at indicated concentrations, or equivalent amounts of DMSO as a control for 1 h, or left untreated, then challenged with wild-type EBOV in the presence of the compounds. Twenty-four hours later, cells were fixed, stained with Hoechst 33342 dye and anti-GP antibody, imaged, and analyzed as described in Fig. 1 (left panel) . EC 50 ± SD values for the compounds are shown in the right panel. (C) HeLa cells were treated with Retro compounds (50 μM) or equivalent concentration of DMSO, Triton X-100 (0.01%, v/v), or left untreated. After 24 h, cell viability was assessed by using CellTiter-Glo luminescent reagent. (D) 293T cells were transfected with EBOV minigenome system as described in Fig. 2A . After 24 h, cells were treated with Retro-2, Retro-2.1, or compound 25 to a final concentration of 20 μM, DMSO, or cycloheximide to the final concentration of 1 μg/mL. Luciferase activity was determined 24 h after treatment. Three independent experiments were performed, and the averages and standard deviations are reported. (E) HeLa cells were pretreated with Retro-2, Retro-2.1, or compound 25 to a final concentration of 20 μM or DMSO as a control for 1 h. Then, samples were incubated with HIV-1 particles pseudotyped with either EBOV-GP (left panel), MLV10A1-GP (middle panel), or VSV-G (right panel) in the presence of the compounds. Luciferase activity was measured after 48 h (RLUs). A one-way ANOVA followed by Dunnett's multiple comparison test for one variable was used to assess a statistical difference between infection efficiencies of EBOV-GP-pseudotyped virus in DMSO and Retro compound-treated cells. A P value < 0.05 was considered statistically significant and is denoted as follows: ** < 0.01, *** < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) thiazole ring for the latter two compounds (Fig. 3A) . Retro-2.1 and compound 25 were tested for inhibition of EBOV infection. Both derivatives blocked infection more efficiently than Retro-2 (Fig. 3B, left  panel) , giving > 3-fold reduction (P < 0.01) in EC 50 for Retro-2, Retro-2.1, and compound 25 to being 12.2 ± 3.0, 3.7 ± 0.8, and 2.5 ± 0.5 μM, respectively. Again, no cytotoxicity was observed for either compound at the maximum tested concentration of 50 μM (Fig. 3C) . When tested in the minigenome assay, Retro-2.1 and compound 25 did not significantly increase luciferase activity beyond the DMSO control (P < 0.01) (Fig. 3D) . In contrast, Retro-2 still gave a 3-fold increase in activity. Taken together, Retro 2.1 and compound 25 appear to be more effective than Retro-2 at inhibiting EBOV infection without the adverse effect of elevating genome replication.
As described above, inhibition of pseudotyped virus infection was evaluated. Consistent with the higher potency of each compound against EBOV-eGFP, when tested at 20 μM, both Retro-2.1 and compound 25 blocked HIV-1-EBOV-GP significantly (P < 0.001), by > 80% and > 67%, respectively (Fig. 3E, left panel) . As seen with Retro-2, infection by either HIV-1-MLV10A1-GP or HIV-1-VSV-G was enhanced by up to 3 or 6 times, respectively, in the presence of each compound (Fig. 3E , middle and right panels, respectively). These results show that, similarly to Retro-2, Retro-2.1 and compound 25 block EBOV entry. Altogether, Retro-2.1 and compound 25 compounds are more potent and do not enhance genome replication in the minigenome assay, therefore being more desirable therapy candidates.
Retro-2, Retro-2.1, and compound 25 inhibit a late step in EBOV entry
To productively infect cells, EBOV is taken into cells by macropinocytosis and conveyed to acidified compartments where the GP requires cleavage by endosomal cysteine proteases before fusion of the viral envelope can occur to release the capsid into the cytoplasm (Chandran et al., 2005) . In vitro, thermolysin treatment can substitute for the endosomal protease to generate activated GP. However, treatment with the Retro compounds at 2 concentrations, 25 μM or 50 μM, still efficiently blocked infection by both uncleaved as well as precleaved EBOV-eGFP virus (P < 0.0001). This outcome was similar to that seen for tetrandrine, an inhibitor of late endosomal trafficking after the proteolysis step (Sakurai et al., 2015) . As expected, treatment with CA074, a cathepsin inhibitor, only impacted virus bearing uncleaved GP, with precleaved GP giving full activity (Fig. 4A ). This work indicated that the Retro compounds, similarly to tetrandrine, inhibited virus entry after the GP proteolysis step.
The cleaved viral GP binds to NPC1, which resides in late endosomal and lysosomal membranes, a necessary step leading to membrane fusion (Carette et al., 2011; Chandran et al., 2005; Miller et al., 2012) . To test whether Retro-2 and its derivatives affect accumulation of EBOV particles in NPC1-containing vesicles, we generated virion-like particles (VLPs) consisting of the GP protein, matrix protein VP40, and nucleoprotein NP. VLPs have been demonstrated to be morphologically indistinguishable from wild-type virus (Johnson et al., 2006; Noda et al., 2006; Warfield et al., 2003) and have become a valuable tool in studies of virus entry into cells. In HeLa cells overexpressing NPC1 and treated with DMSO, 43.9% of VLPs colocalized with the NPC1 signal. Treatment with either Retro-2, Retro-2.1, or compound 25 each showed an increase in the number of VLPs localizing to NPC1-positive compartments, up to 70.3% but was not statistically significant (P > 0.19; Fig. 4B ). Together, our data suggest that the compounds block a step in virus entry that follows GP proteolysis and NPC1 association.
Retro-2 and its derivatives block MARV infection
To test if the Retro compounds have potential as broad-spectrum anti-filoviral compounds, MARV, the most distantly related filovirus of EBOV, was evaluated for inhibition of infection. As shown in Fig. 5 , all three compounds inhibited MARV infection, in the same pattern as for EBOV, with Retro-2.1 and compound 25 being > 2.7 fold more potent than the parent, Retro-2. The EC 50 values for the inhibition curves appeared similar to those for EBOV (Fig. 3B ), 3.2 ± 0.5, 1.9 ± 0.4, and 1.2 ± 0.2 μM for Retro-2, Retro-2.1, and compound 25, respectively. The common inhibition pattern, with Retro-2 being less potent than Retro-2.1 or compound 25, suggests that the target is the same for each virus type through sharing common factors involved in cell entry.
Discussion
In this study, we have analyzed antifiloviral activity of Retro-2 (Stechmann et al., 2010) and its derivatives, compound 25 (Noel et al., 2013) and Retro-2.1 (Gupta et al., 2014) . Each compound inhibited EBOV infection by acting at a late step of virus entry, before escape of the virus particle from the endosome into the cytoplasm. Virions with pre-cleaved GP were as infectious as those with uncleaved GP in the presence of the compounds, indicating that the block occurred after cathepsin cleavage and activation of the GP into a membrane fusioncompetent state. Retro compound treatment also had no effect on the virus particle ability to reach NPC1-positive endolysosomal compartments, an obligatory step that precedes membrane fusion. Our work indicates that while Retro compounds block infection during endosomal trafficking, this pathway appears unaffected up to the last known required step for filoviruses. This suggests that Retro compounds are affecting an as yet unidentified host target that is critical for infection and shared by EBOV and MARV. Further study of the mechanism of action of Retro-type compounds will therefore be important to understand the mechanism of cell infection by filoviruses and to further develop these potential broad-spectrum therapeutic agents.
It is interesting that Retro-2 appeared to elevate EBOV genome transcription and/or replication even though it blocked infection (Figs. 1A and 2A ). This likely reflects that virus entry, being the first step in infection, dictates infection outcome. The increase in minigenome activity after Retro-2 treatment suggests that cell factors that normally inhibit viral gene transcription and/or genome replication are blocked. Similar phenomena were reported for HIV-1, MLV, Hepatitis B virus, and Tomato bushy stunt virus, when an increase in genome copy number was observed when host factors restricting genome replication were blocked (Hrecka et al., 2011; Lin and Nagy, 2013; Mao et al., 2013; Wu et al., 2006) . Alternatively, the ability of Retro-2 to modulate retrograde membrane trafficking to the ER and Golgi (Stechmann et al., 2010) may enhance EBOV minigenome activity by making cellular factors necessary for transcription/replication more available to virus. For positive-strand RNA viruses, viral RNA synthesis is associated with membranes, within organelle-like structures, which are induced by virus infection (Denison, 2008; Salonen et al., 2005) . While such membrane involvement has not been reported for filoviruses, the formation of cytoplasmic inclusion bodies, sites of viral RNA synthesis (Nanbo et al., 2013; Nelson et al., 2016) , may depend on vesicular trafficking of cell factors. In contrast to Retro-2, Retro-2.1 and compound 25 appeared to lack this activity (Fig. 3D ) which was presumably due to the presence of the thiazole adduct in their structure (Fig. 3A) . However, this adduct did not alter the compounds' ability to block virus entry (Fig. 3C) , suggesting this part of the molecule can accommodate additional changes and should be exploited to improve potency.
Retro-2 was initially identified as an inhibitor of ricin and Shiga toxins that require retrograde transport, from early endosomes to the Golgi apparatus, to intoxicate cells (Stechmann et al., 2010) . Later, Retro-2 was shown to inhibit infection by non-enveloped viruses such as polyomaviruses, papillomaviruses, and adeno-associated virus by a similar mechanism of action (Carney et al., 2014; Nelson et al., 2013; Nonnenmacher et al., 2014) . This suggests that these toxins and viruses share a requirement for common cellular factors during transport from early endosomes to the endoplasmic reticulum via the trans-Golgi network. Our findings that Retro-2 and its derivatives block EBOV infection and entry imply that retrograde vesicular trafficking from early endosomes to the Golgi network may also play a role in an early step of filovirus infection. However, filoviruses are not known to localize to the Golgi network, and therefore, a cellular factor dependent on retrograde vesicular transport may be essential for virus entry instead. The fact that Retro-2 and its derivatives did not appear to affect association of virus particles with NPC1-positive compartments (Fig. 4B) suggests that this cellular factor, yet to be identified, acts at a late stage of virus entry, just prior to membrane fusion.
Current filovirus disease countermeasures include investigational therapies consisting of antibody cocktails targeting virus species-specific GPs or nucleoside analogs GS-5734 and BCX4430 which target the highly conserved virus polymerase. Each target is prone to emergence of escape mutants. Host factors are considered less prone to mutation, although generation of drug-resistant viruses have also been reported in Fig. 4 . Retro-2, Retro-2.1, and compound 25 inhibit a late step of EBOV entry. (A) Thermolysin-or mock-treated EBOV-eGFP samples were added onto HeLa cells preincubated with DMSO, 25 μM or 50 μM Retro-2, Retro-2.1, or compound 25, 0.2 μM CA074, or 2 μM tetrandrine. Infected cells were fixed, stained with Hoechst 33342 dye, photographed, and analyzed as described in Fig. 1A . The results are averages of three independent experiments ± SDs are shown. To determine whether virus infection possessing precleaved GP in DMSO-treated cells was statistically different from cells treated with either of the inhibitors, a one-way ANOVA followed by Dunnett's multiple comparison test for one variable was used. A P value was considered statistically significant if < 0.05 and is denoted as follows: **** < 0.0001, ns -not significant. (B) HeLa cells were transfected with a plasmid expressing myc-tagged NPC1. Forty-eight hours after transfection, cells were pretreated with Retro-2, Retro-2.1, or compound 25 to a final concentration of 20 μM or DMSO as control, then incubated with EBOV VLPs in the presence of the compounds. Four hours later, samples were fixed and stained with anti-GP antibody (VLP, green), anti-myc antibody (NPC1, red), and the HCS CellMask Blue dye to stain the cytoplasm and nucleus. Images were obtained as Z-stacks, and three-dimensional images of cells were generated to assess colocalization between virus particles and NPC1. Arrowheads point to examples of VLPs colocalized with NPC1. The percentages of virions colocalizing with NPC1 are reported in the right column. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) cases where a cellular factor important for virus entry was targeted (Berro et al., 2009; Varghese et al., 2017) . In this study, we identified a new class of anti-filovirals, Retro-2 and its dihydroquinazolinone derivatives, Retro-2.1 and compound 25, each blocking virus cell entry of distantly related EBOV and MARV. While not tested here, we expect that other filoviruses will show susceptibility to this drug class, as we are likely targeting a conserved entry mechanism. A drug cocktail consisting of entry inhibitors and other drugs, such as nucleotide analogs, would offer opportunities for better antiviral efficacy, decreased potential toxicity due to lower concentrations of each therapy, reduced development of drug resistant viruses, and targeting a broad range of filoviruses during an outbreak. Our ongoing work is focused on improving anti-filoviral potency of Retro-type compounds before tests in animal models of disease can begin.
